Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses

Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β(2)-agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations. However, the benefits versus side-effects of triple inhaled the...

Descripción completa

Detalles Bibliográficos
Autores principales: Halpin, David M.G., Birk, Ruby, Brealey, Noushin, Criner, Gerard J., Dransfield, Mark T., Hilton, Emma, Lomas, David A., Zhu, Chang-Qing, Lipson, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934530/
https://www.ncbi.nlm.nih.gov/pubmed/29750142
http://dx.doi.org/10.1183/23120541.00119-2017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934530/
https://www.ncbi.nlm.nih.gov/pubmed/29750142
http://dx.doi.org/10.1183/23120541.00119-2017

Ejemplares similares